Protective Role of Coffee in Chronic Liver Disease: A Focus on Processing.

Rofida Khalifa, Khalid Al-Naamani, Mohamed Elbadry, Yuan-Yuan Zhang, Khalid Alswat, Mohamed El-Kassas

Journal: Journal of viral hepatitis 2025;32(10):e70072

PMID: 40919888

Abstract

Chronic liver disease (CLD) is a leading cause of global morbidity and mortality, necessitating effective preventive strategies. Growing evidence is linking coffee consumption with reduced risk of disease progression in various CLDs, including metabolic dysfunction associated steatotic liver disease (MASLD), alcoholic liver disease, hepatitis B and C, autoimmune hepatitis, and a reduction in the risk of hepatocellular carcinoma development. Coffee, a globally consumed beverage, contains bioactive compounds like caffeine, chlorogenic acids, diterpenes, and polyphenols, which may offer hepatoprotective benefits through anti-inflammatory, antioxidant, and metabolic regulatory effects. This narrative review discusses the current evidence demonstrating an inverse correlation between regular coffee intake and CLD progression, highlighting dose-dependent benefits with optimal consumption at three to four cups per day. Potential mechanisms for hepatoprotective effects of coffee involve modulation of the gut-liver axis, epigenetic regulation, and improving liver transaminitis. Additionally, the current review explores the effects of different coffee processing methods, such as roasting levels and brewing techniques, on these protective properties. Coffee's role as an affordable, culturally accepted intervention to mitigate the burden of CLD offers a compelling avenue for future public health strategies. Despite promising evidence, there is a need for further proof to establish the most beneficial coffee preparation methods.

© 2025 John Wiley & Sons Ltd.

Address: Tropical Medicine Department, Faculty of Medicine, Minia University, El Menia, Egypt.; Department of Medicine, Division of Gastroenterology and Hepatology, The Medical City for Military and Security Services, Muscat, Oman.; Endemic Medicine Department, Faculty of Medicine, Helwan University, Cairo, Egypt.; Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu, China.; Liver Disease Research Center, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.